問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Infectious Disease

Digestive System Department

Division of Pediatrics

更新時間：2023-09-19

陳建彰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳建彰

List

14Cases

2017-02-01 - 2024-12-31

Phase III

Active
A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection

  • Condition/Disease

    chronic hepatitis B

  • Test Drug

    Tenofovir Alafenamide

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2025-04-01 - 2027-11-30

Not yet recruiting
A randomized, double-blind, placebo-controlled phase 3 trial is investigating the use of VE303 for the prevention of recurrent Clostridium difficile infection.

  • Condition/Disease

    Double-blind, placebo-controlled trial: Proportion of participants with laboratory-confirmed CDI recurrence by week 8

  • Test Drug

    VE303

Participate Sites
3Sites

Recruiting3Sites

2024-04-01 - 2028-08-03

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-01-23 - 2025-12-24

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

2024-07-01 - 2035-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2023-10-01 - 2034-01-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-05-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-06-01 - 2025-09-17

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2021-12-31 - 2024-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2018-08-01 - 2023-06-26

Phase III

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB